Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Cash from Operations: 2019-2024

Historic Cash from Operations for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to -$100.4 million.

  • Foghorn Therapeutics' Cash from Operations rose 10.21% to -$18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.3 million, marking a year-over-year increase of 14.58%. This contributed to the annual value of -$100.4 million for FY2024, which is 14.99% up from last year.
  • According to the latest figures from FY2024, Foghorn Therapeutics' Cash from Operations is -$100.4 million, which was up 14.99% from -$118.1 million recorded in FY2023.
  • In the past 5 years, Foghorn Therapeutics' Cash from Operations ranged from a high of $193.6 million in FY2022 and a low of -$118.1 million during FY2023.
  • For the 3-year period, Foghorn Therapeutics' Cash from Operations averaged around -$8.3 million, with its median value being -$100.4 million (2024).
  • In the last 5 years, Foghorn Therapeutics' Cash from Operations skyrocketed by 485.30% in 2022 and then crashed by 161.00% in 2023.
  • Over the past 5 years, Foghorn Therapeutics' Cash from Operations (Yearly) stood at -$31.3 million in 2020, then tumbled by 60.61% to -$50.2 million in 2021, then soared by 485.30% to $193.6 million in 2022, then plummeted by 161.00% to -$118.1 million in 2023, then rose by 14.99% to -$100.4 million in 2024.